Skip to main content Accessibility help
×
Hostname: page-component-745bb68f8f-grxwn Total loading time: 0 Render date: 2025-01-09T11:10:27.200Z Has data issue: false hasContentIssue false

Chapter 11 - Parkinson’s Disease

from Section 1: - Basic Introduction

Published online by Cambridge University Press:  07 January 2025

Erik Ch. Wolters
Affiliation:
Universität Zürich
Christian R. Baumann
Affiliation:
Universität Zürich
Get access

Summary

Parkinson’s disease (PD), a typical Parkinson syndrome, is seen as a progressive multisystem neurodegenerative disease with α-synuclein–containing Lewy bodies and neurites, affecting 1–2 per 1000 of the global population. The prevailing view of PD etiology is that it is the result of cell-autonomous and non-autonomous processes, starting in the olfactory nerve and the autonomous nervous system of the gut, spreading retrogradely through synaptically coupled networks in a topographically predictable sequence to postsynaptic brainstem neurons, affecting the nuclear grays of the basal midbrain and forebrain and finally the neocortex. Cell-autonomous processes (e.g., mitochondrial damage and a defective autophagy by lysosomal and ubiquitin proteasome systems) result in pathologic accumulation of intracellular α-synuclein oligomers and aggregates. Non–cell-autonomous processes comprise the spread of synucleinic pathology in dying neurons to neighboring dopaminergic, cholinergic, serotinergic, and adrenergic neurons and/or to astrocytes, microglia, and lymphocytes across brain regions, plus decreased brain-derived neurotrophic factors and/or microglial-induced inflammatory responses.

Type
Chapter
Information
Publisher: Cambridge University Press
Print publication year: 2025

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Parkinson, J. An Essay on the Shaking Palsy. London: Sherwood Neely and Jones; 1817.Google Scholar
Lewy, FH. Paralysis agitans. I. Pathologische Anatomie. In: Handbuch der Neurologie, III. Bd. Berlin: Springer; 1912: 920933.Google Scholar
Carlsson, A, Lindqvist, M, Magnusson, TO. 3,4-Dihydroxyphenylalanine and 5-hydroxy-tryptophan as reserpine antagonists. Nature 1957;180:1200.CrossRefGoogle ScholarPubMed
Birkmayer, W, Hornykiewicz, O. The l-3,4-dioxyphenylalanine (l-DOPA) effect in Parkinson’s akinesia. Wien Klin Wochenschrift 1961;73:7788.Google Scholar
Hornykiewicz, O. Dopamine (3-hydroxytyramine) and brain function. Pharmacol Rev 1966;18:925964.Google ScholarPubMed
Henchcliffe, C, Parmar, M. Repairing the brain: cell replacement using stem cell-based technologies. J Parkinson’s Dis 2018;8:S131S137.CrossRefGoogle ScholarPubMed
Bjorklund, P. Repairing the brain: gene therapy. J Parkinson’s Dis 2018;8:S123S130.CrossRefGoogle ScholarPubMed
Chen-Plotkin, AS, Zetterberg, H. Updating our definitions of Parkinson’s disease for a molecular Age. J Parkinson’s Dis 2018;8:S53S57.CrossRefGoogle ScholarPubMed
Tysnes, OB, Storstein, A. Epidemiology of Parkinson’s disease. J Neural Transm (Vienna) 2017;124:901905.CrossRefGoogle ScholarPubMed
Van den Eeden, S, Tanner, C, Bernstein, A, et al. Incidence of Parkinson’s disease: variation by age, gender and race/ethnicity. Am J Epidemiol 2003;157:10151022.CrossRefGoogle ScholarPubMed
Braak, H, Del Tredici, K, Rub, U, et al. Staging of brain pathology related to sporadic Parkinson’s disease. Neurobiol Aging 2003;24:197211.CrossRefGoogle ScholarPubMed
Maiti, P, Manna, J, Dunbar, GL. Current understanding of the molecular mechanisms in Parkinson’s disease: targets for potential treatments. Transl Neurodegener 2017;6:28.CrossRefGoogle ScholarPubMed
Di Domenico, A, Carola, G, Calatayud, C, et al. Patient-specific iPSC-derived astrocytes contribute to non-cell-autonomous neurodegeneration in Parkinson’s disease. Stem Cell Rep 2019;12:213222.CrossRefGoogle ScholarPubMed
Surmeier, DJ, Obeso, JA, Halliday, GM Selective neuronal vulnerability in Parkinson disease. Nat Rev Neurosci 2017;18:101113.CrossRefGoogle ScholarPubMed
Wolters, ECh, Braak, H. Parkinson’s disease: premotor clinicopathological correlations. J Neural Transm (Vienna) 2006;S70:309320.Google Scholar
Truong, DD, Wolters, ECh. Recognition and management of Parkinson’s disease during the premotor (prodromal) phase. Exp Ther Neurol 2009;9:847857.Google ScholarPubMed
Oppenheimer, DR. Lateral horn cells in progressive autonomic failure. J Neurol Sci 1980;46:393404.CrossRefGoogle ScholarPubMed
Braak, H, Rub, U, Gai, WP, Del Tredici, K. Idiopathic Parkinson’s disease: possible routes by which vulnerable neuronal types may be subject to neuroinvasion by an unknown pathogen. J Neural Transm (Vienna) 2003;10:517536.CrossRefGoogle Scholar
Wolters, ECh, de Munter, H, Steinbusch, H. Parkinson’s disease. In: Wolters, ECh, Baumann, CR, eds. Parkinson Disease and Other Movement Disorders. Amsterdam: VU University Press; 2014: 149162.Google Scholar
De Pablo-Fernandez, E, Lees, AJ, Holton, JL, Warne, TT. Prognosis and neuropathologic correlation of clinical subtypes of Parkinson’s disease. JAMA Neurol 2019;176:470479.CrossRefGoogle Scholar
Erro, R, Picillo, M, Scannapieco, S, Cuoco, S, Pellecchia, MT. The role of disease duration and severity on novel clinical subtypes of Parkinson disease. Parkinsonism Rel Dis 2020;73:3134.CrossRefGoogle ScholarPubMed
Bosboom, JLW, Stoffers, D, Wolters, EC. Cognitive dysfunction and dementia in Parkinson’s disease. J Neural Transm (Vienna) 2004;111:13031315CrossRefGoogle ScholarPubMed
Mendoza-Velásquez, JJ, Flores-Vázquez, JF, Barrón-Velázquez, E, et al. Autonomic dysfunction in α-synucleinopathies. Front Neurol 2019;10:363.CrossRefGoogle ScholarPubMed
St Louis, EK, Boeve, BF. REM sleep behavior disorder: diagnosis, clinical implications, and future directions. Mayo Clin Proc 2017;92:17231736.CrossRefGoogle ScholarPubMed
Valkovic, P, Minar, M, Singliarova, H, et al. Pain in Parkinson’s disease: a cross-sectional study of its prevalence, types, and relationship to depression and quality of life. PLoS One 2015;10:e0136541.CrossRefGoogle ScholarPubMed
Ponsen, MM, Stoffers, D, Booij, J, et al. Idopathic hyposmia as a preclinical sign of Parkinson’s disease. Ann Neurol 2004;56:173181.CrossRefGoogle Scholar
Linda, A. Hershey, LA, Coleman-Jackson, R. Pharmacological management of dementia with Lewy Bodies. Drugs Aging 2019;36:309319.Google Scholar
Hoehn, M, Yahr, M. Parkinsonism: onset, progression and mortality. Neurology 1967;244:28.Google Scholar
Wolters, ECh, van de Werf, Y, van de Heuvel, O. Parkinson’s disease-related impulsive-compulsive complex disorders. J Neurol 2008;255(S5):4856.CrossRefGoogle Scholar
Bougea, A, Maraki, MI, Yannakoulia, M, et al. Higher probability of prodromal Parkinson disease is related to lower cognitive performance. Neurology 2019;92:22612272.CrossRefGoogle ScholarPubMed
Ahn, J, Lee, J-Y, Kim, TW, et al. Retinal thinning associates with nigral dopaminergic loss in de novo Parkinson disease. Neurology 2018;91:10031012.CrossRefGoogle ScholarPubMed
Finberg, JPM, Schwartz, M, Jeries, R, et al. Sensor array for detection of early stage Parkinson’s disease before medication. ACS Chem Neurosci 2018;9(11):25482553.CrossRefGoogle ScholarPubMed
Kilzheimer, A, Hentrich, T, Burkhardt, S, Schulze-Hentrich, JM. The challenge and opportunity to diagnose Parkinson’s disease in midlife. Front Neurol 2019;10:1328.CrossRefGoogle ScholarPubMed
Hughes, AJ, Daniel, SE, Kilford, L, Lees, AJ. The accuracy of the clinical diagnosis of Parkinson’s disease. J Neurol Neurosurg Psychiatry 1992;55:181184.CrossRefGoogle Scholar
Jankovic, J. National Institute of Neurological Disorders and Stroke (NINDS) diagnostic criteria for Parkinson’s disease. J Neurol Neurosurg Psychiatry 2008;79:368376.CrossRefGoogle Scholar
Postuma, RB, Berg, D, Stern, M, et al. MDS clinical diagnostic criteria for Parkinson’s disease. Mov Disord 2015;30:15911601.CrossRefGoogle ScholarPubMed
Mosimann, UP, Muri, MR, Burn, DJ, et al. Saccadic eye movement changes in Parkinson’s disease dementia and dementia with Lewy bodies. Brain 2005; 128:12671276CrossRefGoogle ScholarPubMed
Ferrazzoli, D, Ortelli, P, Zivi, I, et al. Efficacy of intensive multidisciplinary rehabilitation in Parkinson’s disease: a randomised controlled study. J Neurol Neurosurg Psychiat 2017;89:828835.CrossRefGoogle Scholar
Garcia-Agundez, A, Folkerts, A, Konrad, R, et al. Recent advances in rehabilitation for Parkinson’s disease with exergames: a systematic review. J NeuroEngineering Rehabil 2019;16:17.CrossRefGoogle ScholarPubMed
Van der Kolk, NM,De Vries, NM,Kessels, RPC, et al.Effectiveness of home-based and remotely supervised aerobic exercise in Parkinson’s disease: a double-blind, randomised controlled trial. Lancet Neurol 2019;18:9981008.CrossRefGoogle ScholarPubMed

Save book to Kindle

To save this book to your Kindle, first ensure [email protected] is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

Available formats
×

Save book to Dropbox

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.

Available formats
×

Save book to Google Drive

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.

Available formats
×